Chronic diabetes conditions include type 1 diabetes and type 2 diabetes. Potentially reversible diabetes conditions include prediabetes and gestational diabetes. Prediabetes occurs when your blood sugar levels are higher than normal, but not high enough to be classified as diabetes. And prediabetes is often the precursor of diabetes unless appropriate measures are taken to prevent progression. Gestational diabetes occurs during pregnancy but may resolve after the baby is delivered.
October 24th 2024
A recent study found the percentage of type 1 diabetes patients who were prescribed either GLP-1s or SGLT2 inhibitors increased from 0.7% to 8.3% between 2010 and 2023.
Innovations in Diabetes Technology: A New Era of Patient Choice and Opportunities for Pharmacists to Support I...
October 29, 2024 | 1:00 PM ET
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney D...
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Integrated Continuous Glucose Monitoring Implementation and Connectivity: Best Practices, Featuring a Powered ...
1.5 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring Implementation and Connectivity: Best Practices, Featuring a Powered ...
1.5 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Barriers in Integrated Continuous Glucose Monitoring Use, Featuring Patient Counseling Video Vignette...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Barriers in Integrated Continuous Glucose Monitoring Use, Featuring Patient Counseling Video Vignette...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring: What’s New in 2024, Featuring a Device Demonstration and Patient Cou...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring: What’s New in 2024, Featuring a Device Demonstration and Patient Cou...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Strategies for Addressing Cardiovascular Disease, Diabetes, and Chronic Kidney Disease With SGLT2 Inhibitors
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Endocrinopathies of Immune Checkpoint Inhibitor Therapy: Management Strategies for Oncology Pharmacis...
1.0 Credit / Oncology, Endocrinology, Diabetes & Metabolism
View More
Foundations in Continuous Glucose Monitoring
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
SimulatED: Using Continuous Glucose Monitoring Data to Improve Health Outcomes (Pharmacy Technician Credit)
0.75 Credit / Endocrinology, Diabetes & Metabolism
View More
SimulatED: Using Continuous Glucose Monitoring Data to Improve Health Outcomes
0.75 Credit / Endocrinology, Diabetes & Metabolism
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Uncovering the Challenges in Treatment Pathways in AMD and DME
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Navigating Anti-Vascular Endothelial Growth Factor Therapy and Dosing Strategies
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Improving Patient Outcomes in AMD and DME Through the Integration of Specialty Pharmacy Care
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Best Practices for the Integration of Continuous Glucose Monitoring Within the Health System
1.5 Credits / Endocrinology, Diabetes & Metabolism
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Best Practices for the Integration of Continuous Glucose Monitoring Devices Across Community Pharmacy Settings
1.5 Credits / Endocrinology, Diabetes & Metabolism
View More
GLP-1s May Protect Against Cardiovascular Outcomes Regardless of Diabetes Status
October 1st 2024Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.
Slideshow: Diabetes and Mental Health, Diet and Exercise for Prevention of T2D
August 22nd 2024Recent research on diabetes has examined its bidirectional relationship with mental health, the significant increase in prevalence over the last decade, and how both diet and exercise can help prevent type 2 diabetes.
SGLT2i, GLP-1RA Combination Therapy Offers Robust Protection Against Cardiovascular, Kidney Disease
Published: July 8th 2024 | Updated: July 10th 2024When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.